✨ Free AI Report
Curis, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Curis, Inc.
Research Preview

Curis, Inc.: Business Overview, Financials & Competitive Analysis

Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. The company recently transitioned to a pure-play, p...

Analyst-debate audio for Curis, Inc.

AskCyborg analysts argue the bull and bear cases for Curis, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Curis, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
4/ 10Mixed

Cyborg Score thesis

High-risk, high-reward pure-play oncology biotech betting entirely on emavusertib success with acute near-term financing...

Read the full analyst-debate transcript →
Industry Clinical-stage oncology biotechnology; focus on targeted immuno-oncology and precision medicine for hematologic malignancies and solid tumors
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 15, 2026
AI-Verified Research
30+ Page Report

Get the Latest Curis, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Curis, Inc. Overview

Pro stress-test →

Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. The company recently transitioned to a pure-play, pre-commercial biotech after selling its remaining interest in the Erivedge royalty stream in November 2025.

Strategic Profile

Pro stress-test →

Curis is a clinical-stage biotechnology company advancing targeted therapies for cancer treatment, with a focus on immuno-oncology and precision medicine. The company's lead asset, emavusertib, an IRAK4 inhibitor, recently showed a promising 50% MRD conversion rate in a July 2025 data cut-off for its AML triplet study, a critical clinical milestone that could dramatically change its valuation.

Competitive Landscape

Pro stress-test →

Curis's pipeline includes Emavusertib (oral IRAK4 inhibitor in Phase 1/2 for R/R AML/MDS), Fimepinostat (HDAC/PI3K dual inhibitor for B-cell lymphoma), CA-170 (PD-L1/VISTA antagonist), and CA-327 (TIM3/PD-L1 antagonist). Competitors in immuno-oncology include Incyte (Opzelura/ruxolitinib), Celldex (glembatumumab vedotin), and various checkpoint inhibitor programs from large pharma (Merck, Bristol Myers Squibb, Roche/Genentech partnerships).

Industry Context

Curis, Inc. operates in Clinical-stage oncology biotechnology; focus on targeted immuno-oncology and precision medicine for hematologic malignancies and solid tumors.

Key facts

Founded: 2000 · Headquarters: Lexington, Massachusetts · Revenue: $11.65M (TTM, Erivedge royalties) · Market cap: $13.4M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Curis, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Curis, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Opzelura/RuxolitinibJAK inhibitor for cutaneous T-cell lymphoma; competitive immuno-oncology play→Checkpoint inhibitors (PD-1/PD-L1/CTLA-4)Established immuno-oncology standard of care; large pharma competition→HDAC inhibitorsCompeting HDAC/epigenetic modulation approaches for lymphomas→

Compare Curis, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Curis, Inc. operates in Clinical-stage oncology biotechnology; focus on targeted immuno-oncology and precision medicine for hematologic malignancies and solid tumors. See how the rest of the sector scores on the Cyborg framework.

Browse Clinical-stage oncology biotechnology; focus on targeted immuno-oncology and precision medicine for hematologic malignancies and solid tumors research →
NEW · MCP server

Ask your AI assistant about Curis, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Curis, Inc. and its top competitor on Cyborg Score”
“What did Curis, Inc. do this quarter?”
“Is Curis, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Curis, Inc. do?+
Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. The company recently transitioned to a pure-play, p...
What is Curis, Inc.'s Cyborg Score?+
Curis, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Curis, Inc.'s main competitors?+
Named competitors include Opzelura/Ruxolitinib, Checkpoint inhibitors (PD-1/PD-L1/CTLA-4), HDAC inhibitors. The full competitive landscape is in the AskCyborg report.
How can I get the full Curis, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Curis, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Curis, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9Rasan Information Technology Company9Aritzia Inc.9Coherent Corp.9SanDisk Corporation9Zhongji Innolight Co., Ltd.9Cintas Corporation9Lockheed Martin Corporation9ASML Holding N.V.9Broadcom Inc.8Hamilton Insurance Group, Ltd.8Agility Global8Monogram Technologies Inc.8Smartoptics Group ASA8Sidetrade SA8Schweizerische Nationalbank8Funding Circle Holdings plc8BitFuFu Inc.8COMPASS Pathways plc